 |
|
|
Considering aesthetic surgery? You need to do your research and become an informed consumer.
Home
Information about Anti-Aging Products and Their Active
Ingredients
WRINKLE RELAX
HYDRODERM
Strivectin Eye Cream Celebrity Plastic
Surgery Celebrity Cosmetic Surgery Whose Had it??
Bion Ceramic Flat Iron
GoSMILE TOOTH WHITENING
FROWNIES
HOLLYWOOD'S BEST
KEPT SECRET
RICAUD |
(press release from Inamed Corporation)
SANTA BARBARA, Calif.----Sept. 13, 2004--INAMED Corporation, a global health care company, and its partner Ipsen, a European pharmaceutical group, today announced that the trademark Reloxin(TM) has successfully completed the U.S. Patent and Trade Office examination process. As a result, Reloxin(TM) is now the brand name that will be used for the cosmetic indications of Inamed's and Ipsen's Botulinum Toxin Type A product. The product is currently in Phase III clinical trials in the U.S. "Establishing the brand name Reloxin(TM) and the continued progress of the Phase III trials are key events for Inamed and are indicative of our success in advancing this critical project," said Nick Teti, Chairman, President and Chief Executive Officer of Inamed. "The Reloxin(TM) brand represents another step in the pursuit of our goal of having the most complete and dynamic portfolio of facial rejuvenation products." The product is currently marketed and sold in over 60 countries by Ipsen under the trademark DYSPORT(R) for various therapeutic indications and is approved in 9 countries for cosmetic indications. Inamed has exclusive rights to gain regulatory approval and market the product for cosmetic indications in the United States, Canada and Japan. Dysport(R) and Reloxin(TM) are an injectable form of sterile, purified botulinum toxin made from Clostridium botulinum toxin Type A hemagglutinin complex. Small doses of the toxin are injected into targeted muscles to prevent them from contracting. About INAMED Corporation INAMED (Nasdaq:IMDC) is a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the LAP-BAND(R) System for morbid obesity. The Company's website is: www.Inamed.com Forward-Looking Statements This press release contains, in addition to historical information, forward-looking statements. Such statements are based on management's current estimates and expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Inamed is providing this information as of September 13, 2004, and expressly disclaims any duty to update information contained in this press release. Forward-looking statements in this press release include, without limitation, express and implied statements regarding Inamed's anticipated sales, research and development, product development and regulatory approval. These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by Inamed with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements, including but not limited to: exposure to product liability and intellectual property claims; exposure to liabilities that may not be adequately covered by insurance or for which there is no insurance; potential negative publicity concerning product safety; changes in the economy and consumer spending; competition from existing and/or new products; failure or delay of clinical trials; uncertainty in receiving timely regulatory approval or market acceptance for new products; dependence on a single supplier for Inamed's botulinum toxin Type A product; failure to protect Inamed's intellectual property; adverse changes in the regulatory or legislative environment (both in the U.S. and internationally) affecting our business; and failure of some or all of our collaborative partners to perform. The information contained in this press release is a statement of Inamed's present intention, belief or expectation and is based upon, among other things, the existing regulatory environment, industry conditions, market conditions and prices, the economy in general and Inamed's assumptions. Inamed may change its intention, belief or expectation, at any time and without notice, based upon any changes in such factors, in Inamed's assumptions or otherwise. Inamed undertakes no obligation to review or confirm analysts' expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. By including any information in this press release, Inamed does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.
CONTACTS: ************* If You Found this Article Helpful You May Enjoy this article:
and |
PROACTIV SOLUTION ACNE TREATMENT
|
|
Type in your search words below
|
All contents copyright ©2000-2007
- Cosmetic Surgery News - All rights reserved.